โณ Julia can control and manipulate bones, whether living or dead, although controlling the bones of living people takes a lot of energy. She can summon any nearby bones and can use them to do anything, like create weapons and minions to doing menial chores. She can control corpses like puppets using their bones and even control and use her own bones as weapons, although that is more painful.
โ Body Physique: Julia has a tanned and athletic body from spending a lot of time outside. โ Strengths:
โณ She is fearless and doesn't care about other's opinions โณ She can make and use all sorts of weapons โณ She is very creative, especially when using her raiment.
โ Weaknesses:
โณ She runs out of stamina quickly during combat โณ She is limited by the number of bones that is available and that she carries โณ She can be lazy when it comes to doing work and chores
โ Unique Features:
Julia has red eyes and usually wears a bow in her hair. She's often covered in scratches with the occasional smudge of dirt on her face and clothes and always carries a bag that's filled with a variety of animal bones.
โ Personality:
Julia is quite open and cheerful, if somewhat lazy and bratty, with a strong sense of honour and justice. She likes to do whatever she wants, whenever she wants, and has a particular dislike for people trying to force her to do things she dislikes or to change her attitude as she doesnโt care about anyone's opinions, other than a select few. Sheโs fun-loving, slightly mischievous, and has a devil-may-care attitude that, along with her raiment, causes many people to think that she is not all there in the head. She is, in reality, quite observant, although it isn't easy to tell.
โ Likes:
โณ Good food โณ Playing with bones โณ Climbing and exploring
โ Hates/Fears:
โณ Being told what to do โณ Cockroaches โณ Too much work
๐๐ฒ๐ธ๐ฐ๐ป๐ช๐น๐ฑ๐
โณ Julia was born in the outskirts of the kingdom of Valor. Her father was a Shifter while her mother was a Tenebraer who only survived the slaughter because of her childhood friend, a professor at the Academy of Grand Magic, vouched for her. Even though they were safe, Julia's parents were worried for their safety and the safety of their unborn child and moved to a small village near the border to escape the bad reputation of the Tenebraers. Unfortunately, Julia's mother died a couple of years after she was born, having never recovered from the strain of giving birth. Despite his grief, her father cared for her as much as possible and Julia grew up loved and happy.
Their peace was shattered when one day, when she was 12, her Knit manifested itself when she accidently summoned the bones of her neighbour's dead pet, revealing her to be a Tenebraer like her mother. A couple of village children witnessed this and soon, Julia was shunned by most of her peers, causing her to furiously ignored them in turn and opting to spend time developing her new-found powers (that is, when she didn't sic her bones on them). Her father, however, was worried that things would escalate and reluctantly sent her to stay with his late wife's friend who'd saved them before, now the Assistant Headmistress of the Academy, so that she could protect and teach Julia.
At first, Julia resented being sent away to Miss Marisenn Faye and raised havoc, ignoring her father's letters, sneaking out, skipping lessons and meals, ignoring Marisenn's instructions, 'accidentally' breaking furniture, and more. After a couple of months, even the normally cool Marisenn had enough and finally snapped. After being harshly scolded and grounded for her inconsiderate and 'disgraceful' behaviour, Julia finally cooled down. She soon learned to enjoy living with Marisenn, attending lessons (after her attempts to skip them were comically foiled by Marisenn), terrorising exploring the city, practising with her raiment and spending time with Marisenn and her father when he visited. When she finally came of age, Julia attended the Academy of Grand Magic, not that it changed much. She attended the classes (mostly), got decent grades, and spent her time outside. didn't make many friends, but Marisenn was there, which was enough for Julia.
โณ Marisenn can cast realistic illusions that can fool a person's (or, with effort, a group of people's) sense of vision, smell, hearing and even touch, a skill that she's honed through years of training. She can affect most of their senses with one illusion, or she can cast layers which each affect a certain part of the brain, enabling her to create elaborate traps.
โ Position: Assistant Headmistress, Professor of Herbology
โ Body Physique: Marisenn is tall and very thin โ Strengths:
โณ She is detail-oriented and her illusions can be very realistic โณ She can keep calm and think logically in almost all cases โณ She is very perceptive and good at figuring things out
โ Weaknesses:
โณ She is stubborn โณ She can be quite vain and arrogant โณ She doesn't take criticism well
โ Unique Features:
Marisenn is very pale, which, with her tall figure, long, dark hair, calculating eyes and elaborate outfits, causes her to look imposing. She almost always has a smirk on her face and looks deceptively young for her age.
โ Personality:
Marisenn is a calm and collected individual, not overly expressive, who could be depended on to be fair, rational and cool-headed in most situations. She can be serious and stern when the situation calls for it, but she prefers to be laid-back most of them time. She is very confident in her skills and can be arrogant; she seems to be perpetually amused by everything but she enjoys being social and talking to people, and she certainly isn't above messing with them and playing jokes, having a wry sense of humour. She doesn't mind being social and does in fact keep in touch with most friends that she's made, but Marisenn doesn't mind being alone at time, doing nothing other than read or experiment with new techniques
โ Likes:
โณ Sweets โณ Reading and learning โณ Cats
โ Hates/Fears:
โณ Drowning โณ Drinking โณ Being too serious all the time
๐๐ฒ๐ธ๐ฐ๐ป๐ช๐น๐ฑ๐
โณ Marisenn was born and raised in the capital of Valor, having come from a noble family. With her father being a courtier and her mother a Court Mage, she was encouraged from a young age to take interest in her studies and to develop her talents, her Knit and raiment manifesting themselves at a young age. Marisenn didn't mind, her parents weren't at home often and she enjoyed reading and learning, if only to while away the time until they came home. However, she didn't spend all her time cooped up inside, she did leave the house (with company, of course) and she had some friends growing up, including a Tenebraer named Bianka.
When she became of age, Marisenn attended the Academy of Grand Magic, quickly becoming one of the best students and upon graduation, she joined the ranks of the Court Mages. At first elated with her success, Marisenn soon realised that the life of a Court Mage, while fun, just wasn't for her, so she took up a job as Herbology Professor at the Academyโshe always enjoyed studying the plants in her family's greenhouses and gardenโand enjoying it so much that she eventually quit to teach full-time. The kingdom however, wasn't doing that well, with the Queen killed by a rogue Tenebraer and the rest being slaughtered. Marisenn would always feel guilty for not having been there to help and the resulting deaths, but at the moment, she had more immediate concerns: her friend Bianka was pregnant and she was being targetted for her Knit and she tried her hardest to pull strings and get her and her unborn child spared from murder, eventually succeeded although she was under scrutiny for some time after.
Things eventually returned to as normal as they could be, although Marisenn was saddened when she heard about the death of Bianka and stayed in touch with her late friend's family. As the years passed, she was appointed as the Assistant Headmistress, which meant more work, but she didn't mind. She also received word that Bianka's daughter's raiment manifested and as she was unsurprisingly a Tenebraer like her mother, her father asked Marisenn to be her guardian and teacher in hopes that she'd be able to protect the girl, Juliana. Marisenn agreed and while the girl was a terror at first, she calmed down and became a handful instead, not that Marisenn minded. Julia was lively and amusing, and she grew fond of her. Julia eventually grew up and to Marisenn's pride, got accepted at the Academy as well, and while she didn't mind constantly prodding the girl to do better, she'd hoped she'd put in more effort to socialise with her peers.
Posted: Tue Jun 20, 2017 2:41 pm
text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text
text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text
text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text
WHERE place tabtabtabWHO person tabtabtabFEELING mood
text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text
text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text
text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text
WHERE place tabtabtabWITH person tabtabtabFEELING mood
โณ Being a brown bear shifter, Ven possesses great physical ability, being extremely strong and resilient, with a good sense of hearing and smell, and he is also faster than a normal human. He can shift parts of his body (or even his entire body) into that of any animal's, like an shifter, but being a bear shifter, turning into a bear comes much easier.
โ Body Physique: Ven is tall with a large and muscular physique with broad shoulders โ Strengths:
โณ He is very strong and has keen senses โณ He is an extremely good fighter and can use his shifting abilities effectively and creatively โณ He is very determined and doesn't give up
โ Weaknesses:
โณ He is very stubborn and holds grudges โณ He is proud and temperamental and can be easily provoked โณ He is prone to acting before thinking
โ Unique Features:
While he has human features, Ven is quite big and strongly built, similar to a bear, with his left arm looking like a bear's, complete with claws, and his right a human arm, although it looks almost as muscular.
โ Personality:
Ven can be quite rough, being brash, blunt and temperamental. He is quite straightforward and has no problems voicing his opinions, no matter how harsh, and dislikes and hates beating around the bush and outright lying and manipulation. While he is cold and closed-off around people he doesn't know or dislikes, he has no problems talking to and being open around his friends, disliking being left alone. Ven's pride and temper often gets the better of him as he gets easily provoked (usually if he or any of his friends are insulted), which results in him often getting into brawls that left him the victor more often than not. Being impatient, he hates sitting around and waiting, often acting without thinking and making reckless decisions. He is also quite proud and patriotic, holding a grudge against Valor and blaming them for the current poverty-struck state of his country and the suffering he and his fellow countrymen had gone through. Because of all this, Ven can appear to be more brawn than brain, which certainly isn't true; Ven is very creative and can analyse a situation and figure out how to use his shifting ability to the greatest effect, and he can be quite vicious when he needs to be. He does have a soft spot for children, having had a younger sister, and he can't stand to see them suffer and tries to help as much as he could.
โ Likes:
โณ Fish โณ Being busy โณ Children
โ Hates/Fears:
โณ Cold weather โณ Feeling Helpless โณ Snobby rich people โณ Valor
๐๐ฒ๐ธ๐ฐ๐ป๐ช๐น๐ฑ๐
โณ Ven was born to a couple of farmers in one of the various villages within the kingdom of Trendel. His parents were poor, and while they tried their hardest, like most of their village, they still struggled to make ends meet and often skipped meals in favour of feeding their children. From a young age, Ven helped around the farm, and being a bear shifter like his father, he was taught how to use his talents effectively for work.
However, one year, when Ven was eight, there was a terrible drought that destroyed the harvest and caused a famine that affected the entire region and leading to the deaths of many people, including Ven's parents and younger sister. Starving and grieving, Ven was found by his aunt and taken in by his aunt, his father's sister, who from then on raised him. She wasn't much better off than Ven's parents, but being a widow with no children, the two had enough to live off of.
Unlike his parents, Ven's aunt was bitter and disillusioned with the world, and having lost her own children and husband due to an illness, and she harboured a deep resentment for Valor, in part because she believed, like most people, that Valor did indeed sabotage Trendel a long time ago leading to the current state of affairs, and partly because in their desperation, she and her husband saved money to travel there in hopes that they could better treat their sick children, only to be rebuffed and mistreated. She complained about them often to Ven, who was all too willing to agree and believe her because of his own losses.
Like her brother, Ven's aunt was also a bear shifter and she tried to help him control his power, but as he grew older, it became obvious that Ven was talented at using his raiment, which he used to help around the village whenever he could. Believing that his talent shouldn't be wasted, his aunt convinced Ven to focus on his studies to hone his abilities, and eventually, the two of them saved enough money to send Ven to the capital to be apprenticed under a good tutor. Ven spent years under this tutor, who was rather harsh but an effective teacher who helped improve Ven's skill in all sorts of areas, but especially in shifting. Soon, Ven managed to catch the attention of the royal family and was offered a position as a Knight of Trendel, which he gladly accepted, vowing to serve his kingdom to the best of his abilities. Unfortunately, Ven's appointment wasn't well-received by everyone, mostly because of is background and behaviour, and there were many people who believed that he was unworthy of it, but after getting into a fight with Ven, they were soon convinced.
text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text
text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text
text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text text
WHERE place tabtabtabWITH person tabtabtabFEELING mood
Many targeted cancer therapies have been approved by the Food and Drug Administration (FDA) to treat specific types of cancer. Others are being studied in clinical trials (research studies with people), and many more are in preclinical testing (research studies with animals).
How are targets for targeted cancer therapies identified? The development of targeted therapies requires the identification of good targetsโthat is, targets that play a key role in cancer cell growth and survival. (It is for this reason that targeted therapies are sometimes referred to as the product of "rational" drug design.)
One approach to identify potential targets is to compare the amounts of individual proteins in cancer cells with those in normal cells. Proteins that are present in cancer cells but not normal cells or that are more abundant in cancer cells would be potential targets, especially if they are known to be involved in cell growth or survival. An example of such a differentially expressed target is the human epidermal growth factor receptor 2 protein (HER-2). HER-2 is expressed at high levels on the surface of some cancer cells. Several targeted therapies are directed against HER-2, including trastuzumab (Herceptinยฎ), which is approved to treat certain breast and stomach cancers that overexpress HER-2.
Another approach to identify potential targets is to determine whether cancer cells produce mutant (altered) proteins that drive cancer progression. For example, the cell growth signaling protein BRAF is present in an altered form (known as BRAF V600E) in many melanomas. Vemurafenib (Zelborafยฎ) targets this mutant form of the BRAF protein and is approved to treat patients with inoperable or metastatic melanoma that contains this altered BRAF protein.
Researchers also look for abnormalities in chromosomes that are present in cancer cells but not in normal cells. Sometimes these chromosome abnormalities result in the creation of a fusion gene (a gene that incorporates parts of two different genes) whose product, called a fusion protein, may drive cancer development. Such fusion proteins are potential targets for targeted cancer therapies. For example, imatinib mesylate (Gleevecยฎ) targets the BCR-ABL fusion protein, which is made from pieces of two genes that get joined together in some leukemia cells and promotes the growth of leukemic cells.
How are targeted therapies developed? Once a candidate target has been identified, the next step is to develop a therapy that affects the target in a way that interferes with its ability to promote cancer cell growth or survival. For example, a targeted therapy could reduce the activity of the target or prevent it from binding to a receptor that it normally activates, among other possible mechanisms.
Most targeted therapies are either small molecules or monoclonal antibodies. Small-molecule compounds are typically developed for targets that are located inside the cell because such agents are able to enter cells relatively easily. Monoclonal antibodies are relatively large and generally cannot enter cells, so they are used only for targets that are outside cells or on the cell surface.
Candidate small molecules are usually identified in what are known as "high-throughput screens," in which the effects of thousands of test compounds on a specific target protein are examined. Compounds that affect the target (sometimes called "lead compounds" are then chemically modified to produce numerous closely related versions of the lead compound. These related compounds are then tested to determine which are most effective and have the fewest effects on nontarget molecules.
Many targeted cancer therapies have been approved by the Food and Drug Administration (FDA) to treat specific types of cancer. Others are being studied in clinical trials (research studies with people), and many more are in preclinical testing (research studies with animals).
How are targets for targeted cancer therapies identified? The development of targeted therapies requires the identification of good targetsโthat is, targets that play a key role in cancer cell growth and survival. (It is for this reason that targeted therapies are sometimes referred to as the product of "rational" drug design.)
One approach to identify potential targets is to compare the amounts of individual proteins in cancer cells with those in normal cells. Proteins that are present in cancer cells but not normal cells or that are more abundant in cancer cells would be potential targets, especially if they are known to be involved in cell growth or survival. An example of such a differentially expressed target is the human epidermal growth factor receptor 2 protein (HER-2). HER-2 is expressed at high levels on the surface of some cancer cells. Several targeted therapies are directed against HER-2, including trastuzumab (Herceptinยฎ), which is approved to treat certain breast and stomach cancers that overexpress HER-2.
Another approach to identify potential targets is to determine whether cancer cells produce mutant (altered) proteins that drive cancer progression. For example, the cell growth signaling protein BRAF is present in an altered form (known as BRAF V600E) in many melanomas. Vemurafenib (Zelborafยฎ) targets this mutant form of the BRAF protein and is approved to treat patients with inoperable or metastatic melanoma that contains this altered BRAF protein.
Researchers also look for abnormalities in chromosomes that are present in cancer cells but not in normal cells. Sometimes these chromosome abnormalities result in the creation of a fusion gene (a gene that incorporates parts of two different genes) whose product, called a fusion protein, may drive cancer development. Such fusion proteins are potential targets for targeted cancer therapies. For example, imatinib mesylate (Gleevecยฎ) targets the BCR-ABL fusion protein, which is made from pieces of two genes that get joined together in some leukemia cells and promotes the growth of leukemic cells.
How are targeted therapies developed? Once a candidate target has been identified, the next step is to develop a therapy that affects the target in a way that interferes with its ability to promote cancer cell growth or survival. For example, a targeted therapy could reduce the activity of the target or prevent it from binding to a receptor that it normally activates, among other possible mechanisms.
Most targeted therapies are either small molecules or monoclonal antibodies. Small-molecule compounds are typically developed for targets that are located inside the cell because such agents are able to enter cells relatively easily. Monoclonal antibodies are relatively large and generally cannot enter cells, so they are used only for targets that are outside cells or on the cell surface.
Candidate small molecules are usually identified in what are known as "high-throughput screens," in which the effects of thousands of test compounds on a specific target protein are examined. Compounds that affect the target (sometimes called "lead compounds" are then chemically modified to produce numerous closely related versions of the lead compound. These related compounds are then tested to determine which are most effective and have the fewest effects on nontarget molecules.
Many targeted cancer therapies have been approved by the Food and Drug Administration (FDA) to treat specific types of cancer. Others are being studied in clinical trials (research studies with people), and many more are in preclinical testing (research studies with animals).
How are targets for targeted cancer therapies identified? The development of targeted therapies requires the identification of good targetsโthat is, targets that play a key role in cancer cell growth and survival. (It is for this reason that targeted therapies are sometimes referred to as the product of "rational" drug design.)
One approach to identify potential targets is to compare the amounts of individual proteins in cancer cells with those in normal cells. Proteins that are present in cancer cells but not normal cells or that are more abundant in cancer cells would be potential targets, especially if they are known to be involved in cell growth or survival. An example of such a differentially expressed target is the human epidermal growth factor receptor 2 protein (HER-2). HER-2 is expressed at high levels on the surface of some cancer cells. Several targeted therapies are directed against HER-2, including trastuzumab (Herceptinยฎ), which is approved to treat certain breast and stomach cancers that overexpress HER-2.
Another approach to identify potential targets is to determine whether cancer cells produce mutant (altered) proteins that drive cancer progression. For example, the cell growth signaling protein BRAF is present in an altered form (known as BRAF V600E) in many melanomas. Vemurafenib (Zelborafยฎ) targets this mutant form of the BRAF protein and is approved to treat patients with inoperable or metastatic melanoma that contains this altered BRAF protein.
Researchers also look for abnormalities in chromosomes that are present in cancer cells but not in normal cells. Sometimes these chromosome abnormalities result in the creation of a fusion gene (a gene that incorporates parts of two different genes) whose product, called a fusion protein, may drive cancer development. Such fusion proteins are potential targets for targeted cancer therapies. For example, imatinib mesylate (Gleevecยฎ) targets the BCR-ABL fusion protein, which is made from pieces of two genes that get joined together in some leukemia cells and promotes the growth of leukemic cells.
How are targeted therapies developed? Once a candidate target has been identified, the next step is to develop a therapy that affects the target in a way that interferes with its ability to promote cancer cell growth or survival. For example, a targeted therapy could reduce the activity of the target or prevent it from binding to a receptor that it normally activates, among other possible mechanisms.
Most targeted therapies are either small molecules or monoclonal antibodies. Small-molecule compounds are typically developed for targets that are located inside the cell because such agents are able to enter cells relatively easily. Monoclonal antibodies are relatively large and generally cannot enter cells, so they are used only for targets that are outside cells or on the cell surface.
Candidate small molecules are usually identified in what are known as "high-throughput screens," in which the effects of thousands of test compounds on a specific target protein are examined. Compounds that affect the target (sometimes called "lead compounds" are then chemically modified to produce numerous closely related versions of the lead compound. These related compounds are then tested to determine which are most effective and have the fewest effects on nontarget molecules.
Posted: Sun Oct 08, 2017 9:41 am
Many targeted cancer therapies have been approved by the Food and Drug Administration (FDA) to treat specific types of cancer. Others are being studied in clinical trials (research studies with people), and many more are in preclinical testing (research studies with animals).
How are targets for targeted cancer therapies identified? The development of targeted therapies requires the identification of good targetsโthat is, targets that play a key role in cancer cell growth and survival. (It is for this reason that targeted therapies are sometimes referred to as the product of "rational" drug design.)
One approach to identify potential targets is to compare the amounts of individual proteins in cancer cells with those in normal cells. Proteins that are present in cancer cells but not normal cells or that are more abundant in cancer cells would be potential targets, especially if they are known to be involved in cell growth or survival. An example of such a differentially expressed target is the human epidermal growth factor receptor 2 protein (HER-2). HER-2 is expressed at high levels on the surface of some cancer cells. Several targeted therapies are directed against HER-2, including trastuzumab (Herceptinยฎ), which is approved to treat certain breast and stomach cancers that overexpress HER-2.
Another approach to identify potential targets is to determine whether cancer cells produce mutant (altered) proteins that drive cancer progression. For example, the cell growth signaling protein BRAF is present in an altered form (known as BRAF V600E) in many melanomas. Vemurafenib (Zelborafยฎ) targets this mutant form of the BRAF protein and is approved to treat patients with inoperable or metastatic melanoma that contains this altered BRAF protein.
Researchers also look for abnormalities in chromosomes that are present in cancer cells but not in normal cells. Sometimes these chromosome abnormalities result in the creation of a fusion gene (a gene that incorporates parts of two different genes) whose product, called a fusion protein, may drive cancer development. Such fusion proteins are potential targets for targeted cancer therapies. For example, imatinib mesylate (Gleevecยฎ) targets the BCR-ABL fusion protein, which is made from pieces of two genes that get joined together in some leukemia cells and promotes the growth of leukemic cells.
How are targeted therapies developed? Once a candidate target has been identified, the next step is to develop a therapy that affects the target in a way that interferes with its ability to promote cancer cell growth or survival. For example, a targeted therapy could reduce the activity of the target or prevent it from binding to a receptor that it normally activates, among other possible mechanisms.
Most targeted therapies are either small molecules or monoclonal antibodies. Small-molecule compounds are typically developed for targets that are located inside the cell because such agents are able to enter cells relatively easily. Monoclonal antibodies are relatively large and generally cannot enter cells, so they are used only for targets that are outside cells or on the cell surface.
Candidate small molecules are usually identified in what are known as "high-throughput screens," in which the effects of thousands of test compounds on a specific target protein are examined. Compounds that affect the target (sometimes called "lead compounds" are then chemically modified to produce numerous closely related versions of the lead compound. These related compounds are then tested to determine which are most effective and have the fewest effects on nontarget molecules.
2. Please follow all these rules and any instructions given to you by the crew. This guild follows a three-strike system and failure to listen shall result in the guilty party being banned from this guild. These rules also apply to this guildโs Discord server.
3. Be respectful and do not harass, argue or threaten any member or crew. Everyone is to be respected equally in this guild, no matter who youโre talking to and constant and continuous harassment will not be tolerated.
4. Flaming and trolling in this guild is unacceptable. If you are a victim of this treatment or see it happening to others, please notify the mods immediately.
5. This guild is third-person semi-literate to literate, so please avoid writing in first-person, chatspeak, giving one sentence replies and the like.
6. This guild requires activity. If a user is inactive and hasnโt posted anything for two weeks without warning or posting in the absences thread, they will be kicked out and lose any profiles, roles or raiments that they've claimed.
7. Before finishing your profile, you must claim your raiment and any roles that are available and youโre interested in and have them approved before having your profile ready for pending in the Raiment Claim and Role Applications threads. Please do not forget to do your stat roll in your profile thread as well as per the instructions in this thread.
8. Please stay in character, no god-modding, no all-knowing characters or Mary-Sues. Even though this is a fantasy guild, we still need to keep things fair and realistic; everyone has their weaknesses, and everyone has their flaws. Nobody is invincible and no one can know everything. Keep this in mind as you create your character(s).
9. Character pictures! In this guild we use anime, manga, or drawn pictures for characters, preferably not pictures from very well-known anime/manga. No real life pictures, avoid any pictures that are too explicit.
10. Each member is allowed 5 character slots and no more. Please do not create more than 5 characters unless explicitly given permission by the captain.
11. When creating your posting format, please include your characterโs picture, name and a link to their profile. Please ensure that the image isnโt too large; if it is, please edit it using a software like photoshop or gimp, or online editors like imgur or ipiccy. If any quotes are made, please hide them under a โspoilerโ tag.
12. Romance is more than welcome here in this RP. In fact, we encourage it, but it is not actually necessary. Don't force ships unless someone agrees with the plot, but keep the story flowing naturally. Also, keep things appropriate; this RP is rated PG-17. If you are going to do something sexual, then leave it out of Gaia please.
Disclaimer! The crew have the ability to change the rules as they see fit.
Posted: Sat Oct 21, 2017 6:59 pm
tabtabtabtab
Julia smirked at Azuraโs reply that he was lost; that last part didnโt sound convincing, but who was she to rat out her friend? Meanwhile, more students arrived, along with a rather handsome shifter, but Juliaโs attention was caught by Professor Falkovโs arrival and subsequent announcing of the duels to be happening. โIโm sure youโll find someone to duel with, thereโs Sokea and that other shifter, maybe even Professor Falkov,โ she told Azura. โYouโll do great!โ
After sending him one last reassuring smile, Julia approached Griselda, bones flying out of her bag to form a staff that she twirled around in one hand with a confident grin, bouncing lightly on her feet. โHey Zelda, are you ready to fight?โ Zelda was skilled with her sword, but so was Julia and Zelda couldnโt control her bones. It wouldnโt be easy, but it was sure to be fun.
As Zelda had expected, sparring is going to be the main event of this class. Who is she going to be paired off with? Hopefully not Catherine because she couldn't bring herself to harm the princess. Fortunately, she was paired with another student named Juliana. Catherine ended up with the girl named Kissa who asked earlier if she can join in on Griselda's warm up exercises, even though Kissa already begun the warmups. Another pairing between Otsanda and Gin was decided by Professor Falkov, and shortly afterward the fighting began. There was a bit of drama that happened between Otsanda and Gin, and Griselda felt bad that Catherine lost but at least both fighters gave it their all. That was the point of these sparring matches...right? Can Griselda live up to the other matches? Everyone is fighting at their best and the last thing she wants to do is fumble.
Her opponent Juliana approached Griselda with a staff made entirely out of bone. Thats right. Griselda's opponent can manipulate bones to her whim. Should she use the practice weapons or her real ones? She can't underestimate the strength of Juliana's bones, so it may be best to use the real thing. Of course, that meant that she had to do her best not to cut up Juliana. Perhaps focus on using her shield to do most of the damage. She nodded awkwardly toward Juliana before taking her sword and shield from her back. She assumed a stance where her shield arm is in front of her and she is holding her sword as if it were a spear. Her eyes closed momentarily and she took a few deep breathes. Then she opened her eyes. Gone was the shy and awkward girl from before. Right now she is a warrior, eyes that were fierce and an intimidating presence. This fight won't be easy for either one of them, and it is clear that Griselda is going to give it her all.
Seeing Griselda nod and assume a battle stance, giving off a rather fierce aura, Juliaโs smiled turned a touch more manic and shifted back into her own ready stance, gripping her staff diagonally with both hands. Her opponent was going to use her own weapons and while she could handle the sword with no problem, sheโd need to circumvent the shield.
Keeping her eyes trained on Zelda, she stretched out her sense, taking note of all the bones buried in their immediate area and committing them to memory; there wasnโt many but she could make do with what was available. The world narrowed down to just the two of them and Juliaโs eyes sharpened, looking for any weak spots in Zeldaโs stance that she could take advantage of. There were barely any, but that was okay, she could make an opening for herself. Everything slowed down and keeping her smirk on her face, Julia shot forward with no warning. She ducked away from sword and shield and swung her staff at Zeldaโs feet from her defensive side.
Who shall make the first move? Griselda isn't the type to strike first. Its always better to allow her opponent to strike first and continue to provoke them to keep swinging. At the least, her opponent will tire themselves out. If Griselda can figure out an attack pattern, that would be better. So what is the first move? A straight charge toward her. Seems simple enough, but where is Juliana aiming for? Not for her sword, shield, face or body, but her feet. She cannot afford to let Juliana harm her feet. A simple jump allowed her to evade the staff strike. Instead of using her sword fight back, she struck with her shield toward Juliana's body. If it connects, maybe it will knock some wind out of her. It would be a good start for Griselda to try and win this duel.
The shield coming at her was moving too quickly for her to avoid so Julia twisted her staff up to deflect it away from her, following it with a quick and powerful roundhouse kick at Zeldaโs forearm to try and dislodge the shield from her hand.
Griselda's shield was deflected by Juliana's staff, and it was soon dislodged from her arm when she performed a kick. Without that shield, Griselda can't guarantee that Juliana won't be hurt too badly. First, she needed to gain some distance. As Juliana was recovering from the roundhouse kick she delivered, Griselda kicked Juliana in the stomach. Then she ran toward her shield with hope that she will pick it up before Juliana can counter. Griselda could have used her raiment, but she felt that her using her power should be used only if necessary.
Zeldaโs kick connect and Julia flew back and landed heavily on the ground, barely managing to keep a hold on her staff. Damn, that hurt, but she couldnโt let Zelda get her shield back. Catching her breath, she straightened and swept her staff up in an upward motion, propelling the bones buried between Zelda and her shield up out of the ground to shoot at the other girl. She took advantage of that distraction to kick the shield further before using her staff to smack Zeldaโs sword away and striking at her ribcage.
Griselda was so close to reacquiring her shield, but she had to dodge the bones that came out of the ground. Now her shield was kicked further away and Juliana attacked once more. Griselda lost her sword and received a hit to her ribcage. Despite managing to stand her ground, now she doesn't have either one of her weapons. It would be foolish of her to continue fighting without her weapons, so she has to get them back. The issue is that Juliana seems dead set on keeping her away from her weapons. Her only choice is to use her raiment. She did not break eye contact with Juliana in order to not raise any suspicion, but her shield darted toward Juliana from her left side while her sword returned to Griselda's right hand. Regardless if the shield hit Juliana or not, it returned to Griselda's left forearm and she reassumed her stance from the beginning of the duel once more.
Julia saw the shield coming at her at the last minute and dodged, but Zelda managed get her both her weapons and shield back. Looks like they were back to square one but with less energy, time to switch things up. Many small bones rose up to hold Zeldaโs feet in place and try to get her to overbalance as Julia ran once more, twirling her staff and aiming for Zeldaโs head.
Suddenly, Griselda's feet were ensared by bones. How many of these bones does Julia have? It seems endless! Griselda tried to escape but they had a good grip on her feet. Any tighter and her left heel would be in serious pain. In the midst of her trying to escape, two things were happening at once. First, the bones were trying to make her lose her balance. Second, Julia is trying to strike her head. Griselda figured it was best to let the bones trip her so that strike to the head would miss. When that happened, she swung her sword at Julia's legs. If it did connect the worst that can happen is a minor cut on one or both of her legs. afterward, she slashed the bones that had a hold on her feet, rolled away and got back up quickly. There is no way she can keep still anymore. Now its her turn to go on the offensive. First she threw her shield like a disc as a distraction. As soon as she was able to get up close and personal with Julia and had her shield back on her left arm, she unleashed a full on assault with her blade.
Julia tried to dodge Zeldaโs blade on time but she wasnโt quick enough, leaving her with a cut on her left leg that had her hissing in pain. Zelda escaped her bones in the meantime after Julia batted away her shield, she was upon her, attacking viciously with both her both her sword and shield. Julia managed to fend her off successfully, but after a near miss that almost cost her the staff and the pain in her leg, she knew she wouldnโt last against both; she needed to do something. She suddenly hit away first Zeldaโs sword, then her shield and after spinning her staff to gain momentum, she aimed at Zeldaโs sword to hit it out of her hands. As soon as she swung it, Julia concentrated to try and have the shards of bone that Zelda broke to rain down on her to distract her once again. It took more energy than usual, but the distraction would be worth it if it worked.
Griselda can feel the rush of the fight. Her attacks are keeping Julia on the defensive. Just a little more of a push and she can win this! Then she felt a sharp pain in her left heel that made her slow down a bit. It was that bit of a slow down that was the beginning of the end for her. Since she couldn't keep up with the attack, she had to defend herself with her shield from one of Julia's attack. Then she tried to attack once more but her sword got knocked out of her hand once more. She rolled away from Julia, but she didn't get back up. Instead she was grabbing her left heel in pain. Unfortunately, she had another problem coming her way; the shards of broken bone raining down upon her. Once again, she had to continuously roll away in order to avoid getting hit. When the attack stopped, she tried to get up to fight again, but then she collapsed once again and screamed in pain as her left heel hurt immensely. There is no way she can continue this fight, and she can only hope that the professor and Julia will do something about it.
Seeing Zelda lose her sword sent a thrill of satisfaction through Julia, although she raised an eyebrow upon seeing her grabbing her ankle. The rest of the fight, Zelda remained on the defensive to avoid her bones and Julia rushed to take advantage but she stopped short at her scream of pain. That did not sound faked at all. Collapsing her staff, the bones returned to her bag and Julia hurried to see what was wrong. It looked like the ankle she had trouble with earlier, but Julia didnโt touch it lest she make it worse. โProfessor Falkov, it doesnโt look good,โ she called out, her usual smile absent from her face. โI think she need to go to the infirmary.โ
WHERE combat classroom arena tabtabtabWHO each other, Gianna and classmates
In this thread, we've collected some useful resources and links that could help with RPing! Help yourselves to them, and if you have any links that you think belongs in this and that you'd like to share, please PM it to the crew and we'll add it.
Humans are the most widespread beings in Eoana. They're found on almost every documented continent and not are their appearances varied but they also developed many different cultures. They are also more technologically advanced than any other living being in Eoana and are widely considered to be the only civilized species in the land.
All humans are born with some inherent magic, which manifests as their raiments, giving them a unique skill. Not everyone is born with the same amount of magic or talent for their raiment, making some weaker or stronger than others. Some humans are even born with an excess amount of magic which can give them powers beyond that of their raiment, like becoming oracles or having the ability to manipulate their own magic and as well as the surrounding magic in the form of spells and charms, but these are exceedingly rare. The most common forms of non-raiment magic are charms and talismans that are sold by merchants for good fortune, wealth, and youth among other things, and even then, these are nothing more than trinkets.
Humans are not united; in fact, they've formed many different kingdoms each ruled by its own governing body, the two most powerful being Trendel and Valor, and until recently, they've been at constant war with each other and it had been this way for as long as people could remember. There are ruins scattered throughout Eoana that hints at the presence of old civilizations, but barely anything is known about them and most artifacts from these times (especially those imbued with ancient magic) have been gathered and kept under lock and key and in treasuries of various rulers.
Many targeted cancer therapies have been approved by the Food and Drug Administration (FDA) to treat specific types of cancer. Others are being studied in clinical trials (research studies with people), and many more are in preclinical testing (research studies with animals).
How are targets for targeted cancer therapies identified? The development of targeted therapies requires the identification of good targetsโthat is, targets that play a key role in cancer cell growth and survival. (It is for this reason that targeted therapies are sometimes referred to as the product of "rational" drug design.)
One approach to identify potential targets is to compare the amounts of individual proteins in cancer cells with those in normal cells. Proteins that are present in cancer cells but not normal cells or that are more abundant in cancer cells would be potential targets, especially if they are known to be involved in cell growth or survival. An example of such a differentially expressed target is the human epidermal growth factor receptor 2 protein (HER-2). HER-2 is expressed at high levels on the surface of some cancer cells. Several targeted therapies are directed against HER-2, including trastuzumab (Herceptinยฎ), which is approved to treat certain breast and stomach cancers that overexpress HER-2.
Another approach to identify potential targets is to determine whether cancer cells produce mutant (altered) proteins that drive cancer progression. For example, the cell growth signaling protein BRAF is present in an altered form (known as BRAF V600E) in many melanomas. Vemurafenib (Zelborafยฎ) targets this mutant form of the BRAF protein and is approved to treat patients with inoperable or metastatic melanoma that contains this altered BRAF protein.
Researchers also look for abnormalities in chromosomes that are present in cancer cells but not in normal cells. Sometimes these chromosome abnormalities result in the creation of a fusion gene (a gene that incorporates parts of two different genes) whose product, called a fusion protein, may drive cancer development. Such fusion proteins are potential targets for targeted cancer therapies. For example, imatinib mesylate (Gleevecยฎ) targets the BCR-ABL fusion protein, which is made from pieces of two genes that get joined together in some leukemia cells and promotes the growth of leukemic cells.
How are targeted therapies developed? Once a candidate target has been identified, the next step is to develop a therapy that affects the target in a way that interferes with its ability to promote cancer cell growth or survival. For example, a targeted therapy could reduce the activity of the target or prevent it from binding to a receptor that it normally activates, among other possible mechanisms.
Most targeted therapies are either small molecules or monoclonal antibodies. Small-molecule compounds are typically developed for targets that are located inside the cell because such agents are able to enter cells relatively easily. Monoclonal antibodies are relatively large and generally cannot enter cells, so they are used only for targets that are outside cells or on the cell surface.
Candidate small molecules are usually identified in what are known as "high-throughput screens," in which the effects of thousands of test compounds on a specific target protein are examined. Compounds that affect the target (sometimes called "lead compounds" are then chemically modified to produce numerous closely related versions of the lead compound. These related compounds are then tested to determine which are most effective and have the fewest effects on nontarget molecules.
Reply
